Literature DB >> 28886379

Putting p53 in Context.

Edward R Kastenhuber1, Scott W Lowe2.   

Abstract

TP53 is the most frequently mutated gene in human cancer. Functionally, p53 is activated by a host of stress stimuli and, in turn, governs an exquisitely complex anti-proliferative transcriptional program that touches upon a bewildering array of biological responses. Despite the many unveiled facets of the p53 network, a clear appreciation of how and in what contexts p53 exerts its diverse effects remains unclear. How can we interpret p53's disparate activities and the consequences of its dysfunction to understand how cell type, mutation profile, and epigenetic cell state dictate outcomes, and how might we restore its tumor-suppressive activities in cancer?
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28886379      PMCID: PMC5743327          DOI: 10.1016/j.cell.2017.08.028

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  186 in total

Review 1.  Transcriptional regulation by p53: one protein, many possibilities.

Authors:  O Laptenko; C Prives
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

4.  Ferroptosis as a p53-mediated activity during tumour suppression.

Authors:  Le Jiang; Ning Kon; Tongyuan Li; Shang-Jui Wang; Tao Su; Hanina Hibshoosh; Richard Baer; Wei Gu
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

5.  Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

Authors:  Suzanne Leijen; Robin M J M van Geel; Gabe S Sonke; Daphne de Jong; Efraim H Rosenberg; Serena Marchetti; Dick Pluim; Erik van Werkhoven; Shelonitda Rose; Mark A Lee; Tomoko Freshwater; Jos H Beijnen; Jan H M Schellens
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

6.  p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity.

Authors:  Ayala Tovy; Adam Spiro; Ryan McCarthy; Zohar Shipony; Yael Aylon; Kendra Allton; Elena Ainbinder; Noa Furth; Amos Tanay; Michelle Barton; Moshe Oren
Journal:  Genes Dev       Date:  2017-06-12       Impact factor: 11.361

7.  p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Authors:  Serif Senturk; Zhan Yao; Matthew Camiolo; Brendon Stiles; Trushar Rathod; Alice M Walsh; Alice Nemajerova; Matthew J Lazzara; Nasser K Altorki; Adrian Krainer; Ute M Moll; Scott W Lowe; Luca Cartegni; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

8.  A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest.

Authors:  Makoto T Hayashi; Anthony J Cesare; James A J Fitzpatrick; Eros Lazzerini-Denchi; Jan Karlseder
Journal:  Nat Struct Mol Biol       Date:  2012-03-11       Impact factor: 15.369

Review 9.  Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Authors:  David J Olivos; Lindsey D Mayo
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923

10.  An open-label phase I dose-finding study of APR-246 in hematological malignancies.

Authors:  S Deneberg; H Cherif; V Lazarevic; P-O Andersson; M von Euler; G Juliusson; S Lehmann
Journal:  Blood Cancer J       Date:  2016-07-15       Impact factor: 11.037

View more
  526 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

3.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

4.  P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Authors:  Zhongyan Hua; Yue Zhan; Simeng Zhang; Yudi Dong; Min Jiang; Fei Tan; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Apoptosis       Date:  2018-08       Impact factor: 4.677

5.  p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill.

Authors:  James J Manfredi
Journal:  EMBO J       Date:  2019-09-25       Impact factor: 11.598

6.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

7.  The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes.

Authors:  Margot E Bowen; Jacob McClendon; Hannah K Long; Aryo Sorayya; Jeanine L Van Nostrand; Joanna Wysocka; Laura D Attardi
Journal:  Dev Cell       Date:  2019-06-06       Impact factor: 12.270

Review 8.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

Review 9.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

10.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.